Q1 EPS Estimates for Mersana Therapeutics Lowered by Wedbush

Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) - Equities researchers at Wedbush dropped their Q1 2025 earnings estimates for shares of Mersana Therapeutics in a note issued to investors on Monday, March 3rd. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of ($0.25) for the quarter, down from their previous estimate of ($0.24). Wedbush has a "Outperform" rating and a $4.00 price objective on the stock. The consensus estimate for Mersana Therapeutics' current full-year earnings is ($0.62) per share. Wedbush also issued estimates for Mersana Therapeutics' Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.94) EPS, FY2026 earnings at ($0.75) EPS and FY2027 earnings at ($0.70) EPS.

A number of other equities analysts also recently issued reports on MRSN. William Blair initiated coverage on shares of Mersana Therapeutics in a report on Thursday, February 6th. They issued an "outperform" rating for the company. Citigroup began coverage on shares of Mersana Therapeutics in a report on Friday, November 15th. They issued a "buy" rating and a $5.00 target price for the company. Two analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $4.25.

Mersana Therapeutics Stock Performance

NASDAQ MRSN traded down $0.04 on Thursday, hitting $0.50. 2,161,711 shares of the company's stock were exchanged, compared to its average volume of 2,377,792. The firm's 50-day moving average price is $0.73 and its two-hundred day moving average price is $1.54. The firm has a market cap of $62.47 million, a price-to-earnings ratio of -0.82 and a beta of 1.67. The company has a debt-to-equity ratio of 13.35, a current ratio of 2.35 and a quick ratio of 2.35. Mersana Therapeutics has a fifty-two week low of $0.46 and a fifty-two week high of $6.28.

Remove Ads

Mersana Therapeutics (NASDAQ:MRSN - Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.16) by $0.05. The company had revenue of $16.36 million during the quarter, compared to analysts' expectations of $7.71 million. Mersana Therapeutics had a negative return on equity of 401.37% and a negative net margin of 214.20%.

Institutional Investors Weigh In On Mersana Therapeutics

A number of large investors have recently added to or reduced their stakes in the business. Mackenzie Financial Corp acquired a new position in Mersana Therapeutics during the fourth quarter worth about $131,000. Sphera Funds Management LTD. purchased a new position in shares of Mersana Therapeutics during the 4th quarter worth approximately $987,000. Nuveen Asset Management LLC raised its position in shares of Mersana Therapeutics by 53.6% during the 4th quarter. Nuveen Asset Management LLC now owns 232,223 shares of the company's stock worth $332,000 after purchasing an additional 81,022 shares during the last quarter. Millennium Management LLC lifted its stake in Mersana Therapeutics by 206.4% in the 4th quarter. Millennium Management LLC now owns 795,973 shares of the company's stock valued at $1,138,000 after buying an additional 536,190 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. lifted its stake in Mersana Therapeutics by 12.0% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 1,111,998 shares of the company's stock valued at $1,590,000 after buying an additional 118,952 shares in the last quarter. 93.92% of the stock is owned by institutional investors and hedge funds.

About Mersana Therapeutics

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.